A panelist discusses how various factors influence IOL selection for cataract surgery patients, including patient lifestyle ...
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback